Get started

Stockstowatch

$OLB Announces Plan to Offer Cryptocurrency Payment OptionsOLB Group Announces Plan to Offer Cryptocurrency Payment Options via Blockchain Technology on its OMNICOMMERCE Platform and SecurePay TM Gateway OLB’s SecurePay TM Payment Gateway to Enable Merchants to Seamlessly Offer Cryptocurrency Payments $OLB upgraded its SecurePay payment gateway system to support Cryptocurrencies including Bitcoin, Ethereum, USDC and DAI across all merchant platforms. SercurePay is compatible with mobile, tablet-based and cloud infrastructure and will be integrated into the merchants current payment ecosystem, in order to enable the acceptance of Cryptocurrency payments. finance.yahoo.com
NASDAQ:OLB
by AlenCiken
$AUVI Announces Acquisition of the Airocide Technology PlatformApplied UV Announces Acquisition of the Airocide(R) Technology Platform for Airborne Pathogen Reduction Developed with NASA as a patented pathogen killing technology Proprietary photocatalytic oxidation process thoroughly destroys viruses, bacteria, spores, and fungi as well as other carbon-based molecules Airocide® air disinfection technology compliments and expands the SteriLumen platform, together providing a more comprehensive solution for air and surface Accelerates the strategy to grow revenues through complimentary acquisitions Enhances scale in the fast-growing disinfection device market Akida's revenue for the full calendar year 2020 is estimated to be $4.7 million with EBITDA of approximately $921,000. Airocide technology is widely accepted and currently used by nationally recognized brands such as Hard Rock Café, the US Army, Stag's Leap vineyards and many more. finance.yahoo.com
A
by AlenCiken
Pricing of $13.6 million Registered Direct Offering Priced ATMSino-Global Shipping America Announces Pricing of Approximately $13.6 million Registered Direct Offering Priced At-The-Market announced today that it has entered into a securities purchase agreement with certain accredited investors to purchase approximately $13.6 million worth of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement priced at-the-market under Nasdaq rules. Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 1,998,500 shares of the Company's common stock. In a concurrent private placement, the Company has agreed to issue unregistered warrants to purchase up to approximately 1,998,500 shares of the Company's common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $6.805. The warrants will expire 5.5 years from the date of issuance. The purchase price for one share of common stock and a corresponding warrant will be $6.805. finance.yahoo.com
S
by AlenCiken
1
$JG Partners with Kuaishou to Improve Monetization EfficiencyAurora Mobile $JG Partners with Kuaishou to Improve Monetization Efficiency $JG today announced that it has entered into a partnership agreement with Kuaishou Technology (01024.HK) (“Kuaishou”), China’s leading short video content community and social platform, to improve advertising monetization efficiency. By leveraging its powerful artificial intelligence (“AI”) and advanced analysis technologies, Aurora Mobile's advertisement SaaS services will enable Kuaishou to help brands and performance-based advertisers to accurately target potential customers, enhance advertising conversion rate, reduce operational costs, and promote a mutually beneficial relationship between Kuaishou and advertisers on its platform. The short-form video market continues to experience huge growth. Short-form video advertising that features high traffic and conversion rates has become a preferred marketing approach for many brands and performance-based advertisers. According to the cooperation agreement, Aurora Mobile will benefit from a revenue share agreement based on advertising revenues allocated to Kuaishou if the labels provided by Aurora Mobile are used by advertisers on the platform. finance.yahoo.com
NASDAQ:JG
by AlenCiken
$MGNI Surges on Its $1.17 Billion Deal for SpotX$MGNI Magnite to Acquire SpotX Magnite (Nasdaq: MGNI), the largest independent sell-side advertising platform, today announced that it has entered into a definitive agreement to acquire SpotX from RTL Group for $1.17 billion in cash and stock. SpotX is one of the leading platforms shaping CTV and video advertising globally. Deal Creates Largest Independent CTV & Video Advertising Platform Full year 2020 combined company estimated non-GAAP net revenue would have been $350 million on a pro forma basis(1)(2) Combined company Connected TV (CTV) & video net revenue would have represented approximately 67% of total company preliminary non-GAAP pro forma net revenue(1)(2) in Q4 2020 On a combined basis, the CTV business would have nearly tripled to $42 million in Q4 2020 versus Magnite standalone, or approximately 34% of Q4 2020 preliminary non-GAAP pro forma net revenue(1)(2) The non-CTV video business of the combined company would have represented approximately 33% of Q4 2020 preliminary non-GAAP pro forma net revenue(1)(2) SpotX total preliminary non-GAAP net revenue(1)(2) for 2020 was $116 million, of which $67 million was CTV Purchase price consists of $560 million in cash and 14 million shares of Magnite stock, for a total of $1.17 billion based on the closing price of Magnite stock as of February 4, 2021 Magnite’s preliminary results for Q4 2020 include GAAP Revenue of $82 million, up 69% on an as-reported basis, and up 20% on a pro forma basis from Q4 2019, with CTV revenue of $15.3 million, up 53% on a pro forma basis(1) Net income of $5.8 million and Adjusted EBITDA(3) of $29.9 million, representing a 36% adjusted EBITDA margin(4) Together, Magnite and SpotX will serve some of the world’s leading programmers, broadcasters, platforms and device manufacturers, including A+E Networks, Crackle Plus, The CW Network, Discovery, Disney/Hulu, Electronic Arts, Fox Corporation, fuboTV, Microsoft, Newsy, Philo TV, Pluto TV, Roku, Samsung, Sling TV, Tubi, ViacomCBS, Vizio, Vudu, WarnerMedia and Xumo. finance.yahoo.com
NASDAQ:MGNI
by AlenCiken
$AREC Announces Filing of SPAC Registration Statement$AREC American Resources Corporation Announces Filing of SPAC Registration Statement $AREC Company's SPAC is targeting acquisitions in the land holding and resource industry, and will focus on advancing land and resource assets towards a modern-day business model of clean energy, recycling and redevelopment, and social impact. $AREC today announced that American Acquisition Opportunity Inc., a special purpose acquisition company (the "SPAC" or "AAOI"), in which the Company has an indirect investment, filed a Registration Statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission ("SEC") on February 4, 2021 in connection with a proposed initial public offering of its units. The proposed public offering is expected to have a base offering size of $100 million, or up to $115 million if the underwriters' over-allotment option is exercised in full. finance.yahoo.com
NASDAQ:AREC
by AlenCiken
3
Sabra Capital Partners places a $7 target on SupercomSeeking alpha: Sabra Capital Partners places a $7 target on Supercom. Explosive Potential, Limited Downside: We view the base level value of the Company to be $7.00 per share based on a multi-year estimate that revenues will rebound back to $35mm. High conviction. While none of its coronavirus tracking pilots have materialized into a formal, large scale contract, news is gaining momentum in the Company’s backyard, Israel. seekingalpha.com
NASDAQ:SPCB
by AlenCiken
2
Teradata Soars on Strong Earnings and Demand for CloudTeradata Soars on Strong Earnings and Demand for Cloud Shares soared Friday after the data-analytics company reported stronger-than-expected fourth-quarter earnings (triple-digit cloud growth), benefiting from corporate demand for enterprise software and cloud services. Annual recurring revenue (ARR) increased 11% from the prior year period(1) Public cloud ARR increased to $106 million, a 165% increase from the end of 2019(1) Fourth-quarter recurring revenue of $383 million versus $350 million, an increase of 9% reported and 8% in constant currency , and exceeded the Company’s guidance of $371 million to $373 million(1) Fourth-quarter earnings per diluted share (EPS), cash from operations and free cash flow(2) exceeded the Company’s expectations finance.yahoo.com
NYSE:TDC
by AlenCiken
Long CNSP to $4.12 above 3.50Long CNSP to $4.12 above 3.50 CNSP has reentered a trading range if you look left. Symmetrical triangle formation, in confluence with the 786 fib, and monthly resistance levels. 100% measured move on the possible breakout would put us near $4.20, and just under a historical closing range at $4.32 Possible targets above that would be the 1.618 fib at 4.66, or 5.27. All time highs would be 5.71 However, the RSI looks over extended on the 4HR and the macd implies buyers are exhausted on the breakdown, i would look for support at the 786 fib at 3.35 or the 618 at 3.08 Beyond that weekly support would be 2.85 and not unrealistic that we would get a retest of support if we break to the downside. Concluence with the 786 fib and the parallel trading channel in red, would imply we could find support at what used to be our monthly resistance. If we fall out of that trading range, i would look for entry at 2.85 or 2.70
NASDAQ:CNSPLong
by TradingNomadic
1
Why LAIX Stock Price Increased Over 100% in Pre-MarketWhy LAIX Stock Price Increased Over 100% in Pre-Market LAIX is an AI company that provides online English learning products and services in China. Since the company has not announced any news directly and there are no SEC reports to trigger a stock price increase, it appears there was a coordinated move on social media to drive the price up, similar to the reason why ATA Creativity Global went up more than 936% yesterday. I am seeing references to LAIX in stock trading groups on Facebook, Discord chat rooms, stock trading subreddits, Twitter hashtags, and YouTube channels before the market open. Many of these posts mentioned the advantages of the high volume and relatively low float of the stock. I noticed a user on StockTwits point out that the short percentage yesterday was 85% and there were no available shares to short on WeBull. “If you’re short on this ticker may I suggest you cover now before it gets out of control,” warned the user. Since the business model appears to be similar to ATA Creativity Global, it also appears that there is a sympathy play in effect as well. And since the company shares have a relatively small float and there is a high squeeze probability, day traders are also jumping on LAIX. pulse2.com
L
by AlenCiken
$LIZI | Trade Plan Friday 05, 2021$LIZI has been on fire. 3 green days, I was stalking a short entry around 11:00am but did not get it as it showed strength. For the past 3 days in a row, it's been pushing at market open, I expect same today. Average time to start fading is around 11:00am - 12:00pm, today I am looking at scalping once it hits the premarket high of 20.09 (very strong resistance). Above 20, it will probably squeeze a little, but I can see today will be first red day. Short at sight of weakness, breaking uptrend lines, be careful of any share volume above 250K/min. Long at Buy area indicated, confluence of support and trendline (around 13.50 - 13.75 area). Trade your plan, manage your risk. GL & Happy Friday.
LShort
by archi_trader
23andMe to Merge with Virgin Group's VG Acquisition Corp. SPAC23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics. - 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses - The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion - 23andMe CEO and Co-Founder Anne Wojcicki and Virgin Group's Sir Richard Branson are each investing $25 million into the $250 million PIPE and are joined by leading institutional investors including Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital and Foresite Capital - The pro forma cash balance of the combined company will exceed $900 million at closing Completion of the transaction, estimated in the second calendar quarter of 2021. 23andMe is the only consumer genetic testing company with multiple FDA clearances for over-the-counter health and carrier status reports. 23andMe's existing equity holders will roll 100% of their equity into the combined company. Assuming no public shareholders of VG Acquisition Corp. exercise their redemption rights, 23andMe will be capitalized with up to $984 million in cash to fund operations and support new and existing growth initiatives. finance.yahoo.com
V
by AlenCiken
REE Automotive to List on NASDAQ Through Merger with $VCVCREE Automotive to List on NASDAQ Through Merger with 10X Capital Venture Acquisition Corp REE’s fully-flat and modular EV platforms are based on proprietary REEcorner technology, positioned to become the cornerstone of next-generation e-Mobility. The transaction is expected to provide more than $500 million of gross proceeds to the Company. This includes funds from a fully committed $300 million PIPE with participation from long-term strategic investors including Koch Strategic Platforms, Mahindra & Mahindra and Magna International. As a result of outsized demand, the PIPE offering was meaningfully oversubscribed and upsized. Pro forma equity value of the merger is approximately $3.6 billion and pro forma enterprise value of $3.1 billion, at the $10.00 per share PIPE price and assuming minimal 10X SPAC shareholder redemptions. targeting a $700 billion total addressable market REE has an orderbook comprised of signed indications of interest for over 250,000 platforms, representing 27% of their total cumulative expected revenue of $19.1 billion by 2026. The transaction will accelerate mass production of REEcorner technology and modular EV platforms, expected to begin in 2023. The proposed transaction expected to be completed by the end of the first half of 2021. www.businesswire.com
V
by AlenCiken
2
“Strong Buy” Penny Stock With Over 200% Upside on the Horizon“Strong Buy” Penny Stock With Over 200% Upside on the Horizon a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. finance.yahoo.com
NASDAQ:CNSP
by AlenCiken
2
Why $NAKD Stock crashed Down Sharply from last week?Why $NAKD Stock crashed Down Sharply from last week? The WallStreetBets short squeeze continued to unravel this week with investors pocketing gains and latecomers hoping for a second bounce. A number of factors are driving the ongoing sell-off as $NAKDe stock peaked last week. The first is that many short-sellers closed out their bets as the stocks soared last week, riding a massive short squeeze and gamma squeeze. Second, savvy traders who rode the stocks up sold it to take profits. Third, fundamentals matter, and stocks will naturally revert to their mean barring any significant change in fundamentals. After all, a stock is a part-ownership in a business, not a lottery ticket. So the possibility of a short squeeze is diminished, and the "easy money" has come and gone. Traders who now buy any of these three stocks are banking on another pump-and-dump rally to lift them. Investors should also be aware that $NAKD stock is still significantly above historical trading level and fundamentals are weak, meaning stock could fall significantly further. www.fool.com
N
by AlenCiken
7